The Department of Biochemistry at NEIGRIHMS organised a “Pre-Conference CME (ACCLMPCON 2024)” on advancements in Alzheimer’s disease here yesterday.
The aim was to sensitise the medical fraternity regarding the availability of CSF-based biomarkers of Alzheimer’s disease, ie Beta Amyloid (Aβ42), Total Tau, and PhosphoTau, which will help in the early diagnosis of Alzheimer’s disease before the symptoms appear.
The CME was inaugurated in the presence of NEIGRIHMS Director Dr Nalin Mehta. Other dignitaries present included Prof Dr Suvomoy Chakraborty, Dean (Academic) In-charge, and Prof Dr C Daniala, MS of NEIGRIHMS.
Dr Mehta stressed upon the need for early diagnosis and treatment of dementia in general and Alzheimer’s disease in particular as their incidence is gradually increasing in the older population. He also suggested that younger doctors should be well equipped with the knowledge of dementia diagnosis so that they can guide the patients for proper treatment.
Delegates and resource persons from different parts of the country as well as from different disciplines of medicine attended the event and shared their knowledge and expertise in the field of dementia and Alzheimer’s disease in particular.
